CLINICAL EFFECTIVENESS OF CASIRIVIMAB AND IMDEVIMAB COMPARED WITH STANDARD OF CARE IN COVID-19: A SYSTEMATIC REVIEW AND META-ANALYSIS
Monoclonal antibodies cazirivimab and imdevimab are used as a combination drug in the treatment of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The aim of this study was to investigate the clinical effectiveness of the combined medication of casirivimab and imdevimab in patients with COVID-19.
Searches were conducted in the electronic databases of PubMed, Scopus, Cochrane Library, and Web of Science to identify relevant articles from 2020 to 2023. Additionally, a manual search was performed in primary review sources and key studies. There were no language restrictions for the studies. The quality assessment of the studies was conducted using the ROBINS-I tool. Data analysis was performed using Review Manager Software version 5.4.
A total of 14 studies involving 461598 patients were included in the study. The results of the meta-analysis showed that there was a significant difference between the casirivimab and imdevimab and standard of care groups in terms of mortality rate (odds ratio [OR]: 0.29, %95, 0.10-0.86, P<0.00001), hospitalization rate (OR: 0.35, %95, 0.22-0.44, P<0.00001), need for oxygen therapy (OR: 0.23, %95, 0.12-0.46, P<0.00001), hospitalization or death (OR: 0.40, %95, 0.38-0.43, P<0.00001), and mechanical ventilation (OR: 0.19, %95, 0.08-0.43, P<0.00001).
The results of this meta-analysis study showed that casirivimab and imdevimab is an effective treatment in reducing mortality rate, hospitalization rate, need for oxygen therapy, hospitalization or death, and mechanical ventilation in patients with COVID-19.
- حق عضویت دریافتی صرف حمایت از نشریات عضو و نگهداری، تکمیل و توسعه مگیران میشود.
- پرداخت حق اشتراک و دانلود مقالات اجازه بازنشر آن در سایر رسانههای چاپی و دیجیتال را به کاربر نمیدهد.